Abstract | BACKGROUND: METHODS: RESULTS: Among 2,874 patients included, the first anticoagulant used was UFH in 26%, enoxaparin in 59%, and fondaparinux in 15%. Respective figures for final anticoagulant were 17%, 56%, and 27%. Although 3 centers did not use fondaparinux (community centers with catheterization laboratory), the overall rate of use of fondaparinux, as initial and final anticoagulant, increased at the expense of the use of enoxaparin. We observed a growing proportion of patients with a switch from UFH to either enoxaparin or fondaparinux, ranging from 5% at the beginning to 25% at the end of the study. Patients treated with UFH were older, had more comorbidities, were at higher risk, and received fewer guidelines-recommended treatments. In patients submitted to angioplasty and treated with fondaparinux, a bolus of 60 IU/kg of UFH was added. After adjustment, 30-day mortality and combined end point rates were higher in patients treated with UFH. Irrespective of the type of acute coronary syndromes, patients treated with enoxaparin or fondaparinux had similar outcomes. CONCLUSIONS:
|
Authors | François Schiele, Nicolas Meneveau, Marie France Seronde, Vincent Descotes-Genon, Joanna Dutheil, Romain Chopard, Fiona Ecarnot, Jean-Pierre Bassand, Reseau de Cardiologie de Franche Comte |
Journal | American heart journal
(Am Heart J)
Vol. 159
Issue 2
Pg. 190-8
(Feb 2010)
ISSN: 1097-6744 [Electronic] United States |
PMID | 20152216
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright (c) 2010 Mosby, Inc. All rights reserved. |
Chemical References |
- Anticoagulants
- Enoxaparin
- Polysaccharides
- Heparin
- Fondaparinux
|
Topics |
- Acute Coronary Syndrome
(drug therapy, mortality)
- Aged
- Anticoagulants
(therapeutic use)
- Enoxaparin
(therapeutic use)
- Female
- Fondaparinux
- Heparin
(therapeutic use)
- Humans
- Male
- Polysaccharides
(therapeutic use)
- Time Factors
|